Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC. (October 2022) - VanderWalde, A.; Spigel, D.R.; Darbonne, W.C.; Yu, W.; Kim, Y.; Whitehead, Z.; Szado, T.; Slater, D.; Zuniga, R.; Arrowsmith, E.